National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
501 total, page 9 of 11
Effects of Miconazole on Blood Flow
NCT00004575
Vitamin Replacement in Abetalipoproteinemia
NCT00004574
Magnetic Resonance Imaging to Detect Blood Vessel Inflammation in Patients Undergoing Peripheral Balloon Angioplasty
NCT00004549
MRI Evaluation of Chest Pain
NCT00001961
Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects
NCT00001963
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
NCT00001965
Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
NCT00001960
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
NCT00001962
Genetic Analysis of African-Americans With High Blood Pressure
NCT00353925
Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia
NCT00001144
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
NCT00000620
Study of TNFR:Fc (Enbrel) in the Treatment of Asthma
NCT00001893
Electromechanical Mapping to Evaluate Heart Muscle
NCT00001895
A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001894
Sample Collections From the Airways of Asthmatic Patients
NCT00001888
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
NCT00001890
Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle
NCT00001891
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
NCT00003838
Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis
NCT00001885
Specimen Collection for Individuals With Lung Disease Associated With Rheumatoid Arthritis
NCT00001884
Stem Cell Transplantation for Metastatic Solid Tumors
NCT00001880
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease
NCT00001881
Collections of Blood and Stool Samples in Patients With Acute Hepatitis
NCT00001879
Quality Control of Cardiopulmonary Exercise Equipment
NCT00001883
Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease
NCT00001889
Real Time 3-Dimensional Stress Echocardiography
NCT00001886
Factors Involved in Asthma and Airway Inflammation
NCT00001887
Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy
NCT00001874
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
NCT00001873
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
NCT00001872
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
NCT00001877
Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
NCT00001878
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
NCT00001871
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
NCT00029380
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
NCT00003552
Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)
NCT00001869
Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women
NCT00001752
Comparing Treatments for Multiple Myeloma
NCT00001750
Study of the Effects of Temperature on Metabolism in Human Muscle
NCT00001753
Medical Treatment for Diamond Blackfan Anemia
NCT00001749
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies
NCT00001748
Racial Differences in Control of Blood Vessel Tone and Blood Flow
NCT00001747
Screening for Inherited Heart Disease
NCT00001746
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease
NCT00027196
Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
NCT00027183
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
NCT00003553
The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients
NCT00001742
Study of Inherited Changes of Receptors Located on Blood Vessels
NCT00001741
Evaluation of Left Ventricular Volumes by Real-Time 3-Dimensional Echocardiography
NCT00001740
Magnetic Resonance Imaging of the Blood Vessels of the Heart
NCT00001638
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.